CTLA4 and metastatic melanoma: For decades no new therapeutic agent has been approved for metastatic melanoma by the FDA until a recent study, which showed survival benefit of a monoclonal antibody targeting a regulatory checkpoint, CTLA-4, in T-cells [5] and led to the approval of ipilimumab in 2011.